Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Sellas Life Sciences Group, Inc. (SLS) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Sellas Life Sciences Group, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1390478.
Total stock buying since 2016: $84,600.
Total stock sales since 2016: $2,336,848.
Total stock option exercises since 2016: $224,568.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 50,000 | $84,600 | 0 | $0 | 0 | $0 |
| 2022 | 0 | $0 | 9,806 | $25,513 | 0 | $0 |
| 2021 | 0 | $0 | 3,198 | $19,996 | 0 | $0 |
| 2018 | 0 | $0 | 23,277 | $29,189 | 0 | $0 |
| 2017 | 0 | $0 | 2,363,941 | $1,985,563 | 0 | $0 |
| 2016 | 0 | $0 | 126,875 | $276,587 | 126,875 | $224,568 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-06 | 10,000 | $14,800 | 0 | $0 | 0 | $0 |
| 2025-05 | 40,000 | $69,800 | 0 | $0 | 0 | $0 |
| 2022-12 | 0 | $0 | 9,806 | $25,513 | 0 | $0 |
| 2021-12 | 0 | $0 | 3,198 | $19,996 | 0 | $0 |
| 2018-12 | 0 | $0 | 23,277 | $29,189 | 0 | $0 |
| 2017-06 | 0 | $0 | 500 | $273 | 0 | $0 |
| 2017-02 | 0 | $0 | 2,363,441 | $1,985,290 | 0 | $0 |
| 2016-06 | 0 | $0 | 126,875 | $276,587 | 126,875 | $224,568 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-12 | Van Nostrand Robert L | Buy | 10,000 | 1.48 | 14,800 |
| 2025-05-30 | Wasman Jane | Buy | 20,000 | 1.69 | 33,800 |
| 2025-05-22 | Kalin Katherine Bach | Buy | 20,000 | 1.80 | 36,000 |
| 2022-12-05 | Stergiou Angelos M. (President and CEO) | Sale | 6,494 | 2.61 | 16,936 |
| 2022-12-05 | Burns John Thomas (Senior VP, Finance & CAO) | Sale | 1,159 | 2.59 | 3,001 |
| 2022-12-05 | Wood Barbara A (EVP, Gen. Counsel, Corp. Sec.) | Sale | 2,153 | 2.59 | 5,576 |
| 2021-12-02 | Stergiou Angelos M. (President and CEO) | Sale | 2,120 | 6.25 | 13,252 |
| 2021-12-02 | Burns John Thomas (VP, Finance & Corp Controller) | Sale | 231 | 6.27 | 1,447 |
| 2021-12-02 | Wood Barbara A (EVP, Gen. Counsel, Corp. Sec.) | Sale | 847 | 6.25 | 5,297 |
| 2018-12-31 | Stergiou Angelos M. (President and CEO) | Sale | 23,277 | 1.25 | 29,189 |
| 2017-06-20 | Nisi Rudolph (Director) | Sale | 500 | .55 | 273 |
| 2017-02-08 | Gerber Sander | Sale | 2,363,441 | .84 | 1,985,290 |
| 2016-06-01 | Dunlap Ryan (Former Chief Financial Officer) | Sale | 126,875 | 2.18 | 276,587 |
| 2016-06-01 | Dunlap Ryan (Former Chief Financial Officer) | Option Ex | 126,875 | 1.77 | 224,568 |
Insider trading activities including stock purchases, stock sales, and option exercises of SLS listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Sellas Life Sciences Group, Inc. (symbol SLS, CIK number 1390478) see the Securities and Exchange Commission (SEC) website.